Editorial

Anticoagulation for venous thromboembolism

BMJ 2007; 334 doi: 10.1136/bmj.39161.665579.BE (Published 29 March 2007)
Cite this as: BMJ 2007;334:645

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. John W Eikelboom, thrombosis physician (eikelbj@mcmaster.ca),
  2. Jeffrey S Ginsberg, thrombosis physician,
  3. Jack Hirsh, thrombosis physician
  1. Department of Medicine, McMaster University, Hamilton, ON, Canada L8N 8Z5

    Longer duration of treatment does not reduce risk of recurrence unless continued indefinitely

    The optimal duration of anticoagulant therapy for the treatment of venous thromboembolism has been the subject of many randomised trials over the past 15 years.1 2 The results indicate no clear advantage for many patients of prolonging warfarin beyond three to six months, because of the risk of bleeding and the inconvenience. The annual incidence of major bleeding in patients who take warfarin for longer than three months is 2-3%, with an estimated case fatality rate of 9.1% (95% confidence interval 2.5% to 21.7%).3 Also, duration of treatment has little effect on the long term risk (after the first three months) of recurrence. Trials have shown that the frequency of recurrence at two to three years is similar in patients taking three months or 12 months of oral anticoagulation.1 2 …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular